2026年4月17日，北京大学博雅讲席教授、昌平实验室领衔科学家、生命科学学院邓宏魁课题组在国际学术期刊《细胞》（Cell）上发表了题为“p53 safeguards chemical reprogramming of human somatic cells toward pluripotency”的研究论文。该研究发现，关键肿瘤抑制因子p53在化学重编程中发挥核心保护作用，打破了“p53阻碍细胞 ...

2026年4月17日，北京大学基础医学院邓宏魁院士课题组在Cell上发表了题为“p53 safeguards chemical reprogramming of human somatic cells toward pluripotency”的研究论文（图1）。 图1. 该研究相关论文首页截图 该研究发现，关键肿瘤抑制因子p53在化学重编程中发挥核心保护作用，打破了“p53阻碍细胞重编程”的传统认 ...

Cancer incidence rises sharply with age, yet the biological mechanisms that make older patients more vulnerable to treatment failure remain poorly ...

A clinical trial to reverse age-related vision conditions using stem cell treatment could finally deliver on the promise of a ...

A single-atom nanozyme mimicking cytochrome c oxidase restores mitochondrial energy production in stem cells, shifting their ...

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into a suppressed state. This previously unrecognized molecular interaction, ...

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This strategy may help to overcome immunotherapy resistance in pancreatic ...

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...